ADTX
Aditxt, Inc. Common Stock NASDAQ Listed Jun 30, 2020$0.01
+6.00%
vs $0.01
Mkt Cap $178
usd
52w Low $0.00
0.0% of range
52w High $32950.80
50d MA $1.95
200d MA $2763.93
P/E (TTM)
—
EV/EBITDA
—
P/B
0.0x
Debt/Equity
—
ROE
-762.7%
P/FCF
—
RSI (14)
43.00
ATR (14)
$0.01
Beta
—
50d MA
$1.95
200d MA
$2763.93
Avg Volume
830.2M
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.
CIK (SEC)
Phone
909-488-0844
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | — | -14.80 | +100.0% | 4.05 | +2.7% | -5.2% | -4.7% | +4.9% | -2.6% | +1.6% | — |
| Nov 17, 2025 | AMC | — | -73.15 | — | 33.92 | +1.2% | -3.8% | -14.7% | -17.5% | -2.8% | +28.0% | — |
| Aug 14, 2025 | AMC | — | -392.05 | — | 931.12 | +0.0% | -1.0% | +3.9% | +2.8% | -4.6% | -1.0% | — |
| May 15, 2025 | AMC | — | -922.73 | — | 1455.44 | +1.2% | +3.1% | +5.4% | +4.0% | -4.4% | +4.6% | — |
| Mar 24, 2025 | AMC | — | -4556.78 | +99.8% | 6481.68 | -1.0% | -2.9% | -1.6% | -9.9% | -19.0% | -10.2% | — |
| Nov 18, 2024 | AMC | — | — | -1.9% | 76614.00 | -2.7% | +3.2% | -3.2% | -4.2% | +4.4% | +18.0% | — |
| Aug 19, 2024 | AMC | — | — | -56.6% | — | — | — | — | — | — | — | — |
| May 20, 2024 | AMC | — | — | -174.5% | — | — | — | — | — | — | — | — |
| Apr 2, 2024 | AMC | -29.81 | -36.82 | -23.5% | — | — | — | — | — | — | — | — |
| Nov 14, 2023 | AMC | — | — | -714.2% | — | — | — | — | — | — | — | — |
| Aug 14, 2023 | AMC | — | — | +68.2% | — | — | — | — | — | — | — | — |
| May 15, 2023 | AMC | -2.78 | -1.31 | +52.9% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 16 | Dawson James | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 | Takeover Time 2026 LLC10% | — | Sell | 3,420,439 | $0.02 | $68K | — | +0.00% | — |
| Jun 22, 2026 | HRT FINANCIAL LP10% | — | Sell | 5,120,480 | $0.02 | $92K | — | -80.00% | -16.67% |
| Jun 18, 2026 | HRT FINANCIAL LP10% | — | Buy | 7,340,178 | $0.01 | $95K | 2,406,438 | -80.00% | -16.67% |
| Jun 17, 2026 | DRW Securities, LLC10% | — | Sell | 126,772 | $0.01 | $1K | — | +90.00% | +15.00% |
| Jun 16, 2026 | HRT FINANCIAL LP10% | — | Sell | 3,132,480 | $0.01 | $41K | — | +90.00% | +15.00% |
| Jun 15, 2026 | HRT FINANCIAL LP10% | — | Buy | 2,114,344 | $0.01 | $30K | 344,964 | +127.27% | -80.00% |
| Jun 12, 2026 | HRT FINANCIAL LP10% | — | Buy | 4,252,767 | $0.02 | $68K | 2,459,308 | -59.63% | -77.70% |
| Jun 11, 2026 | BANK OF AMERICA CORP /DE/10% | — | Sell | 15 | $0.01 | $0 | 49 | -15.50% | +113.54% |
| Jun 11, 2026 | BANK OF AMERICA CORP /DE/10% | — | Buy | 3 | $0.01 | $0 | 64 | -15.50% | +113.54% |
| Jun 11, 2026 | BANK OF AMERICA CORP /DE/10% | — | Buy | 1 | $0.02 | $0 | 58 | -15.50% | +113.54% |
| Jun 11, 2026 | HRT FINANCIAL LP10% | — | Sell | 2,833,463 | $0.01 | $40K | — | +1.57% | +92.00% |
| Jun 10, 2026 | HRT FINANCIAL LP10% | — | Buy | 725,330 | $0.02 | $14K | 1,040,004 | -2.31% | +127.27% |
| Jun 9, 2026 | HRT FINANCIAL LP10% | — | Sell | 878,659 | $0.03 | $29K | 314,674 | -2.31% | +127.27% |
| Jun 9, 2026 | Gong Sandie10% | — | Sell | 100,000 | $0.07 | $7K | — | -29.73% | -59.63% |
| Jun 8, 2026 | HRT FINANCIAL LP10% | — | Buy | 1,423,493 | $0.05 | $70K | 1,193,333 | -2.31% | +127.27% |
| Jun 5, 2026 | HRT FINANCIAL LP10% | — | Sell | 735,462 | $0.06 | $46K | — | -42.08% | +1.57% |
| Jun 4, 2026 | HRT FINANCIAL LP10% | — | Buy | 843,622 | $0.08 | $64K | 505,302 | -42.08% | +1.57% |
| Apr 24, 2026 | HRT FINANCIAL LP10% | — | Sell | 29,404 | $0.28 | $8K | 88,377 | -12.25% | -28.24% |
| Apr 23, 2026 | HRT FINANCIAL LP10% | — | Sell | 3,811 | $0.29 | $1K | 117,781 | -12.25% | -28.24% |
8-K
Aditxt, Inc. -- 8-K Filing
Jun 24
8-K · 3.02
!! High
Aditxt, Inc. -- 8-K 3.02: Unregistered Securities Offering
Jun 23
8-K · 1.01
!! High
Aditxt, Inc. -- 8-K 1.01: Material Agreement
Jun 10
8-K · 3.02
!! High
Aditxt, Inc. -- 8-K 3.02: Unregistered Securities Offering
Jun 9
8-K · 5.02
!!! Very High
Aditxt, Inc. -- 8-K 5.02: Executive Change
Jun 1
8-K
Aditxt, Inc. -- 8-K Filing
May 29
NT 10-Q
!! High
Aditxt, Inc. -- Late Quarterly Report -- Distress Signal
May 15
8-K
Aditxt, Inc. -- 8-K Filing
I cannot provide a meaningful analysis based on this summary, as it only describes SEC filing classification procedures without disclosing any material business event or financial information relevant to ADTX investors.
May 1
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
ADTX's new agreement with Seven Knots likely involves manufacturing, distribution, or licensing that could expand revenue streams or reduce costs, making the deal material enough for investors to evaluate its financial impact on earnings.
Apr 14
8-K
Unknown — 8-K Filing
Aditxt acquired or integrated Ignite Proteomics LLC and filed audited financials, enabling securities offerings through S-3 registrations, suggesting expansion into proteomics diagnostics that could drive future revenue growth.
Apr 7
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis from this filing excerpt, as it contains only technical XBRL metadata and references without substantive business information about ADTX's material event or announcement.
Apr 2
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Adtx is conducting an at-the-market offering to raise capital, diluting existing shareholders but providing financial flexibility for operations without immediate debt obligations.
Mar 30
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
ADTX's acquisition of BACK is now final, potentially expanding ADTX's product portfolio or market reach, which could drive revenue growth and justify higher valuations if synergies materialize successfully.
Mar 13
8-K · 7.01
! Medium
Aditxt, Inc. -- 8-K 7.01: Regulation FD Disclosure
Aditxt disclosed material information through a press release via Form 8-K, though the specific details require reviewing the attached exhibit to assess impact on shareholders.
Mar 5
8-K
Aditxt, Inc. -- 8-K Filing
Aditxt shareholders voted to approve a non-binding advisory measure supporting a proposed name change for the company, though final approval remains pending.
Feb 13
Institutional (13F) — Top 4
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Danske Bank A/s | 3 | $3 | New | Mar 2026 |
| 2 | Ifp Advisors, Inc | 1 | $1 | New | Mar 2026 |
| 3 | Ubs Group Ag | 1 | $1 | New | Mar 2026 |
| 4 | Western Wealth Management, Llc | 1 | $1 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$178
Enterprise Value
$5K
P/E (TTM)
—
Forward P/E
—
PEG Ratio
—
P/B
0.00x
P/S
0.33x
P/FCF
—
EV/EBITDA
—
Shares Out
904K
Financials (TTM)
Revenue
$14K
Net Income
-$52.0M
EBITDA
-$50.7M
Free Cash Flow
—
Op Cash Flow
—
EPS Basic
$-1153.83
EPS Diluted
$-1490.72
EPS Forward
—
Gross Margin
19.9%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
—
Total Liab.
—
Total Equity
—
Cash
—
LT Debt
—
Book Value/Sh
$150.17
Debt/Equity
—
Current Ratio
0.31
Quick Ratio
—
Returns & Growth
ROE
-762.7%
ROA
-259.1%
ROIC
—
Rev Growth YoY
—
EPS Growth YoY
—
Price Returns
2W
-54.1%
1M
-95.4%
3M
-100.0%
6M
-100.0%
12M
-100.0%
Technicals
52W High
$32950.80
52W Low
$0.00
50d MA
$1.95
200d MA
$2763.93
RSI (14)
43.00
ATR (14)
$0.01
Beta
—
Avg Volume
830.2M
Dividends
Div Rate
—
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 4:07pm
· Source: financialmodelingprep.com